S&P 500   3,783.28 (-0.20%)
DOW   30,273.87 (-0.14%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
S&P 500   3,783.28 (-0.20%)
DOW   30,273.87 (-0.14%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
S&P 500   3,783.28 (-0.20%)
DOW   30,273.87 (-0.14%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
S&P 500   3,783.28 (-0.20%)
DOW   30,273.87 (-0.14%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
NASDAQ:SLNO

Soleno Therapeutics - SLNO News Today

$1.72
-0.07 (-3.91%)
(As of 10/5/2022 05:29 PM ET)
Add
Compare
Today's Range
$1.70
$1.83
50-Day Range
$1.63
$28.80
52-Week Range
$1.60
$13.50
Volume
37,525 shs
Average Volume
85,406 shs
Market Capitalization
$13.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Get Soleno Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SLNO and its competitors with MarketBeat's FREE daily newsletter.



SLNO Media Mentions By Week

SLNO Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

SLNO
News Sentiment

1.35

0.80

Average
Medical
News Sentiment

SLNO News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

SLNO Articles
This Week

1

0

SLNO Articles
Average Week

SourceHeadline
finance.yahoo.com logoSoleno Therapeutics Announces Initiation of Randomized Withdrawal Study of DCCR for the Treatment of Prader-Willi Syndrome
finance.yahoo.com - October 3 at 10:48 AM
finance.yahoo.com logoFeneca (FENC) Gets FDA Nod for Cancer-Related Hearing Loss Drug
finance.yahoo.com - September 22 at 10:39 PM
finance.yahoo.com logoIronwood's (IRWD) Functional Constipation Study in Kids Succeeds
finance.yahoo.com - September 7 at 4:11 PM
finance.yahoo.com logoSoleno Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
finance.yahoo.com - September 6 at 9:41 AM
reuters.com logoSoleno Therapeutics Inc
reuters.com - August 21 at 7:26 PM
finance.yahoo.com logoSoleno Shares Surge On Regulatory Update For Its Prader-Willi Syndrome Hopeful
finance.yahoo.com - July 20 at 6:25 PM
finance.yahoo.com logoSoleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome
finance.yahoo.com - July 20 at 8:24 AM
finance.yahoo.com logoSoleno Therapeutics Announces Presentation of DCCR Data at the 11th International Prader-Willi Syndrome Organisation Conference
finance.yahoo.com - July 11 at 6:13 PM
finance.yahoo.com logo4 Small Stocks to Bet on in an Upbeat Drugs Industry
finance.yahoo.com - July 6 at 5:10 PM
finance.yahoo.com logoWhy Soleno Therapeutics Shares Are Surging Today
finance.yahoo.com - June 14 at 5:35 PM
seekingalpha.com logoSoleno Therapeutics surges on positive data from Prader-Willi syndrome treatment
seekingalpha.com - June 13 at 5:11 PM
finance.yahoo.com logoSoleno Therapeutics Presents Long Term Data for DCCR Showing Metabolic and Body Composition Improvements in Patients with PWS
finance.yahoo.com - June 13 at 5:11 PM
finance.yahoo.com logoSoleno Therapeutics Announces Presentations at ENDO 2022
finance.yahoo.com - June 7 at 11:01 AM
finance.yahoo.com logoSoleno Therapeutics Announces Presentations at the 2022 European Congress of Endocrinology
finance.yahoo.com - May 19 at 5:45 PM
finance.yahoo.com logoSoleno Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
finance.yahoo.com - May 17 at 10:52 AM
finance.yahoo.com logoSoleno Therapeutics Announces Presentation of Long-Term Hyperphagia and Behavioral Data in Patients Receiving DCCR for Treatment of Prader-Willi Syndrome
finance.yahoo.com - May 2 at 6:22 PM
finance.yahoo.com logoHigh school seniors saw a problem — so they started a biotech company
finance.yahoo.com - April 13 at 4:14 PM
finance.yahoo.com logoHow Covid stymied a Peninsula company's drug aimed at calming insatiable appetites
finance.yahoo.com - April 11 at 7:39 PM
finance.yahoo.com logoSoleno Therapeutics Announces Closing of Approximately $15 Million Underwritten Public Offering
finance.yahoo.com - April 1 at 12:05 PM
nasdaq.com logoTRVN To Report Data In Mid-year, TSHA Trims Workforce, FDA Decision On SPRO's NDA To Be Delayed?
nasdaq.com - April 1 at 7:05 AM
finance.yahoo.com logoSoleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results
finance.yahoo.com - March 31 at 8:58 PM
seekingalpha.com logoSoleno Therapeutics stock slumps on pricing ~$15M stock offering
seekingalpha.com - March 29 at 9:50 AM
seekingalpha.com logoSoleno Therapeutics stock slides on proposed equity offering
seekingalpha.com - March 28 at 6:49 PM
finance.yahoo.com logoSoleno Therapeutics Announces Proposed Underwritten Public Offering
finance.yahoo.com - March 28 at 6:49 PM
finance.yahoo.com logoHere's Why Soleno Therapeutics (NASDAQ:SLNO) Must Use Its Cash Wisely
finance.yahoo.com - March 27 at 4:55 PM
finance.yahoo.com logoRunning for Research – Prader-Willi Syndrome to Fund Multi-Center Study of DCCR in Early Phase Prader-Willi Syndrome
finance.yahoo.com - March 9 at 11:15 AM
nasdaq.com logoSoleno Therapeutics, Inc. (NASDAQ:SLNO) insiders sold US$2.9m worth of stock, possibly signalling a downtrend
nasdaq.com - February 8 at 3:49 PM
finance.yahoo.com logoSoleno Therapeutics to Participate in the BIO CEO & Investor Conference
finance.yahoo.com - February 8 at 10:45 AM
seekingalpha.com logoSoleno Therapeutics gets FDA update on DCCR program for Prader-Willi Syndrome
seekingalpha.com - January 24 at 10:37 AM
finance.yahoo.com logoSoleno Therapeutics to Participate in the LifeSci Partners 11th Annual Corporate Access Event
finance.yahoo.com - January 5 at 12:40 PM
finance.yahoo.com logoDown 13.9% in 4 Weeks, Here's Why Soleno Therapeutics, Inc. (SLNO) Looks Ripe for a Turnaround
finance.yahoo.com - November 24 at 12:59 PM
finance.yahoo.com logoSoleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
finance.yahoo.com - November 19 at 7:53 PM
finance.yahoo.com logoSoleno Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial Results
finance.yahoo.com - November 10 at 7:29 PM
nasdaq.com logoIs Soleno Therapeutics (NASDAQ:SLNO) In A Good Position To Invest In Growth?
nasdaq.com - November 9 at 2:13 PM
nz.finance.yahoo.com logoPear Therapeutics Announces Additional Coverage Decisions and Formulary Adoption of its Prescription Digital Therapeutics
nz.finance.yahoo.com - September 25 at 2:22 AM
finance.yahoo.com logoSoleno Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference
finance.yahoo.com - September 23 at 1:07 PM
msn.com logoSoleno Therapeutics' DCCR Shows Benefit On Hunger, Behavioral Parameters
msn.com - September 8 at 1:02 PM
finance.yahoo.com logoSoleno Therapeutics Announces Positive Data Showing Continued Significant Improvements in Symptoms of PWS following One Year Treatment with DCCR
finance.yahoo.com - September 8 at 1:02 PM
nasdaq.com logoSoleno Therapeutics Inc Shares Approach 52-Week Low - Market Mover
nasdaq.com - August 20 at 7:43 AM
nasdaq.com logoSoleno Therapeutics Inc Shares Fall 0.2% Below Previous 52-Week Low - Market Mover
nasdaq.com - August 18 at 5:30 PM
finance.yahoo.com logoSoleno Therapeutics Provides Corporate Update and Reports Second Quarter 2021 Financial Results
finance.yahoo.com - July 28 at 6:11 PM
nasdaq.com logoSoleno Therapeutics, Inc. Common Stock (SLNO)
nasdaq.com - July 16 at 6:24 PM
msn.com logoBRIEF-Soleno Therapeutics Provides Regulatory Update On Dccr For The Treatment Of Prader-Willi Syndrome
msn.com - July 6 at 9:24 AM
finance.yahoo.com logoSoleno Stock Shoots Higher as Diazoxide Choline Gets US Orphan Drug Tag for Glycogen Storage Disease
finance.yahoo.com - June 2 at 3:08 PM
finance.yahoo.com logoSoleno Therapeutics Receives Orphan Drug Designation from FDA for Diazoxide Choline for the Treatment of Glycogen Storage Disease Type 1a
finance.yahoo.com - June 2 at 10:07 AM
finance.yahoo.com logoSoleno Therapeutics to Participate in the Oppenheimer Rare & Orphan Disease Summit
finance.yahoo.com - May 20 at 12:49 PM
finance.yahoo.com logoSoleno Therapeutics Provides Corporate Update and Reports First Quarter 2021 Financial Results
finance.yahoo.com - May 5 at 5:18 PM
finance.yahoo.com logoSoleno Therapeutics' DCCR Treatment Shows Improvement In Multiple Behavioral Domains In Prader-Willi Syndrome Patients
finance.yahoo.com - May 4 at 3:38 PM
finance.yahoo.com logoSoleno Therapeutics Announces Presentation of Positive Behavioral Data from Ongoing Extension Study of DCCR for Treatment of Prader-Willi Syndrome
finance.yahoo.com - May 4 at 10:37 AM
finance.yahoo.com logoSoleno Therapeutics Participates in Prader-Willi Syndrome (PWS) DCCR Town Hall
finance.yahoo.com - April 15 at 12:21 AM
Get Soleno Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SLNO and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:SLNO) was last updated on 10/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.